AstraZeneca Q4 Core Earnings Beat Estimates Despite Esing COVID Vaccine Demand
Feb 9, 2023
AstraZeneca PLC (LON:AZN) posted better-than-expected core income in the fourth quarter, thanks to strong demand for its cancer and rare disease therapies that helped make up for waning sales of its COVID-19 vaccine. Core earnings per share during the three months ended on
Recent Comments